Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.33 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210913 | 0.86 | NPC1 (0.39) | MAPK14KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5210889 | 0.85 | NPC1 (0.40) | MAPK14KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5210074 | 0.85 | RXRB (0.38) | MAPK14KDM4ENPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4806911 | 0.84 | MEN1 (0.36) | ENPP2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5216930 | 0.83 | RAB9A (0.37) | MAPK14KDM4ENPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4807978 | 0.83 | NPC1 (0.37) | MAPK14KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4812628 | 0.76 | GPR119 (0.42) | KDM4ENPC1RAB9A | |
| SCHEMBL7127489 | 0.76 | MEN1 (0.37) | ENPP2MAPK14KDM4ENPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4809310 | 0.76 | MEN1 (0.35) | ENPP2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5209066 | 0.75 | CYP2D6 (0.49) | ENPP2NPC1RAB9AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20050267173-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-12-01 | — | — | US | disclosed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | ENPP2 193/4885MAPK14 3700/4885KDM4E 3323/4885 |
| US-20050267173-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ENPP2 121/4885MAPK14 3086/4885KDM4E 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.